The My Child Matters Programme: The Effect of the Implementation of a Childhood Cancer Care Network (ReNaCI) in the Treatment Abandonment of Acute Lymphoblastic Leukemia in Paraguay This is an ASCO ...

The aim of this study was to determine the maximum tolerated dose of a fixed dose of docetaxel when combined with continuous infusion ifosfamide, with and without G-CSF support, in the treatment of ...

A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00–10:00) flat infusion of 5-fluorouracil (5-FU) ...

The usefulness of PET/CT and diffusion-weighted MRI in pancreatic cancer. Background: In USA, adjuvant chemoradiotherapy is standard treatment for resectable gastric cancer. But compared to the ...

The demographics of this cohort are presented in Table 1. The mean age at diagnosis was 53 years in the HSR group and 58 in the non-HSR group (P = .02). All 58 patients, including 36 ovarian cancers ...

Docetaxel is a chemotherapy drug that is used to treat several forms of cancer. On March 22nd 2006, the United States Food and Drug Administration (FDA) approved the use of docetaxel in combination ...

Dec. 4, 2003 (San Antonio) — Docetaxel (Taxotere) produced better overall survival and longer time to progression than paclitaxel (Taxol) in a randomized head-to-head trial of the two taxanes widely ...

The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made. The U.S. Food and Drug ...

Docetaxel is a chemotherapy drug that is used to treat several different types of cancer. On the 19th of May 2004, the United States Food and Drugs Administration (US FDA) approved the use of ...

BRIDGEWATER, NJ – June 5, 2004 – Aventis announced today the results of a phase III trial using Taxotere® (docetaxel) Injection Concentrate when added to a standard therapy for nonresectable locally ...

The European Medicines Agency (EMEA) has been formally notified by Sanofi-Aventis Pharma S.A. of its decision to withdraw its application for an extension of indication for the centrally authorised ...

Treatment with Dato-DXd reduced the risk of disease progression or death by 25% vs docetaxel. The Food and Drug Administration (FDA) has accepted the Biologics License Application for datopotamab ...